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• A Waters Alliance HPLC system (Model 2965) with a 
photodiode array detector (Model 2998) and Empower3 
software was used for sample analysis.
• The method validation parameters studied were linearity, 
precision, accuracy, robustness, and system suitability.
• The stationary phase used was a Phenomenex Gemini C18 
column (4.6 mm x 15 cm x 3.0 mcm) at a temperature set to 
400C.
• The mobile phase was composed of methanol and water in 
a ratio of 65:35 (v/v). 
• Detection wavelength was 205nm while the flow rate was 
maintained at 1.00 mL/min for a run time of 15 minutes.
• The forced degradation study examined estriol's stress 
threshold by subjecting reference standard solutions to 
acidic and alkaline degradation, oxidative degradation, 
photodegradation (visible light and UV), and thermal 
degradation.
Most method validation parameters – linearity, precision, accuracy, robustness, 
system suitability – met the respective acceptance criteria established by ICH 
guidelines.
In the forced degradation study, there was significant oxidative, visible light, 
UV, and thermal degradation but insignificant acidic or alkaline degradation. 
Additionally, no degradants co-eluted with estriol.
The method will be utilized to quantify estriol in multiple compounded 
preparations from two different compounding pharmacies.
o Estriol (E3) is an estrogen hormone that plays an important role in uterine 
growth and fetal health during pregnancy. E3 is produced by the placenta 
during fetal development and is detected at high levels around 3 weeks 
before childbirth. Through hormone replacement therapy, E3 has been 
studied in clinical trials in the treatment of peri and postmenopausal 
symptoms such as hot flashes, mood swings, and sleep disturbances as well 
as benefits for promoting better urogenital health.1
o Although there are several FDA approved commercial hormone products to 
treat peri and postmenopausal symptoms2, some patients may need a 
specific dosage form prepared by a specialized compounding pharmacy.3
o Compounded HRT can be administered via multiple routes with various 
dosage forms including: oral troches, vaginal creams/inserts, tablets, and 
capsules.3
o Currently, the United States Pharmacopeia (USP) does not offer an official 
monograph for determining estriol compounded in glycerinated gelatin.4
o It is, therefore, necessary to establish a validated stability indicating method 
that can quantify estriol in a glycerinated gelatin base. 
BACKGROUND
This developed and validated method is suitable for both routine 
potency/strength testing as well as stability testing of estriol in 
compounded glycerinated gelatin troche dosage forms. 
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Table 1. Summarized Forced Degradation Results
Table 2. System Suitability Results
Figure 1. Representative chromatograms comparing 
100mcg/mL standard (top) to hydrogen peroxide 3 day forced 
degradation sample (bottom)
The objective of this study was to develop a validated stability indicating HPLC 
method that quantifies estriol in compounded glycerinated gelatin troches.
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Degradation Description of Procedure Time (hours) Ave. % Yield
0.1 N HCl Water bath shaker, 25±5⁰C, 130 rpm 0.5 96.69 %
0.1 N NaOH Water bath shaker, 25±5⁰C, 130 rpm 24 105.03 %
0.1 N H2O2 Water bath shaker, 25±5⁰C, 130 rpm 72 25.89 %
Visible Light Bench lamp light, 25±5⁰C 24 81.64 %
UV Light Hood UV light, 25±5⁰C 168 81.97 %
Thermal Digital heatblock, 60±2⁰C 24 83.80 %
Parameter Result Acceptance Criteria
Ave. Tailing Factor (Tf) 1.76 ≤ 2.0
Ave. Asymmetry Factor (As) 1.97 % ≤ 2.0 %
Ave. % RSD Peak Area 0.26 % ≤ 1.0 %
Ave. % RSD Retention Time 0.37 % ≤ 1.0 %
Ave. # Theoretical Plates (N) 2714.37 > 2000
Ave. Height Equivalent to N (HETP) 0.0058 cm < 0.1cm
